title: Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.
abstract: OBJECTIVE
  To investigate the association between genetic risk variants for age-related macular degeneration (AMD) and response to intravitreal ranibizumab in Korean patients with neovascular AMD.
  
  
  METHODS
  This prospective study included 273 treatment-naive patients (273 eyes) who underwent 5 monthly injections (Months 0, 1, 2, 3, and 4) of intravitreal ranibizumab for neovascular AMD. Patients were genotyped for 23 single-nucleotide polymorphisms within 12 AMD-relevant genes. For each polymorphism, genotypic association with good response at Month 5, predetermined as visual improvement of ≥ 8 Early Treatment Diabetic Retinopathy Study letters from baseline, was investigated with logistic regression analysis adjusted for age, gender, smoking, baseline Early Treatment Diabetic Retinopathy Study letter, central retinal thickness, lesion area, and type of choroidal neovascularization.
  
  
  RESULTS
  At Month 5, visual acuity improved by 9.1 ± 17.6 letters from baseline, and 136 patients (49.8%) were classified as good responders. In logistic regression, no tested polymorphism showed statistically significant association with favorable visual outcome at Month 5. When unadjusted for multiple tests, AA genotype for VEGF rs699947 had an increased chance of good response compared with other genotypes (odds ratio, 3.61; 95% confidence interval, 1.42-9.18; P = 0.0071).
  
  
  CONCLUSIONS
  In this Korean neovascular AMD cohort, there was no statistically significant effect of genotype on early visual outcome after ranibizumab treatment.
authors.affiliation: *Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea; †Department of Ophthalmology, National Medical Center, Seoul, Korea; ‡Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; §DNA Link Inc, Seoul, Korea; ¶GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom; and **Sensory Organs Institute, Medical Research Center, Seoul National University, Seoul, Korea.
authors.forename: Un Chul
authors.initials: UC
authors.lastname: Park
authors.forename: Joo Young
authors.initials: JY
authors.lastname: Shin
authors.forename: Sang Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Eun Soon
authors.initials: ES
authors.lastname: Shin
authors.forename: Jong Eun
authors.initials: JE
authors.lastname: Lee
authors.forename: Linda C
authors.initials: LC
authors.lastname: McCarthy
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Newcombe
authors.forename: Chun-Fang
authors.initials: CF
authors.lastname: Xu
authors.forename: Hum
authors.initials: H
authors.lastname: Chung
authors.forename: Hyeong Gon
authors.initials: HG
authors.lastname: Yu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D044466:Asian People; D004396:Coloring Agents; D005136:Eye Proteins / Q000235:genetics*; D005260:Female; D005451:Fluorescein Angiography; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D000069579:Ranibizumab; D056910:Republic of Korea; D012307:Risk Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D005136:Eye Proteins; D005819:Genetic Markers; D007208:Indocyanine Green; D000069579:Ranibizumab